Clarity Pharmaceuticals has dosed the first participant in the therapeutic phase of its Phase I/II theranostic trial of 64Cu/67Cu SAR-bisPSMA theranostic products for metastatic, castrate-resistant prostate cancer (mCRPC) treatment.

The SECuRE trial has been designed for evaluating Clarity’s Targeted Copper Theranostics (TCTs) 64Cu/67Cu SAR-bisPSMA in these patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial’s first participant was treated at the Urology Cancer Center and GU Research Network located in Omaha, Nebraska.

The single arm, multi-centre, dose escalation study will identify and treat Prostate-Specific Membrane Antigen (PSMA) expressing mCRPC using TCTs.

It initially underwent the dosimetry phase with 64Cu SAR-bisPSMA for determining the product biodistribution and dosimetry over multiple time points.

A safety review committee has collected and reviewed the data and recommended to progress the trial into therapeutic applications with 67Cu SAR-bisPSMA.

The trial will determine the safety and efficacy of 67Cu -SAR-bisPSMA as a therapy.

Clarity executive chairman Dr Alan Taylor said: “Prostate cancer is one of the largest oncology indications and there is a significant unmet need for improved diagnosis and therapy of patients with this insidious disease.

“Moreover, the preliminary data suggests the optimised PSMA product could deliver clinical benefits in oncology indications beyond prostate cancer, which we are excited to explore in the near future.

“Clarity’s TCTs are the next-generation platform that aims to resolve these challenges and enable the radiopharmaceutical field to expand significantly in the large oncology market, addressing multiple large cancer indications.”

The 64Cu SAR-bisPSMA is designed to visualise the PSMA expressing lesions and choose candidates for subsequent therapy.

The company stated that the SECuRE trial has planned a cohort expansion for up to 44 participants in the US.